These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26107799)

  • 21. Advances in hepatitis C therapies.
    Mariño Z; Lens S; Gambato M; Forns X
    Expert Opin Pharmacother; 2015; 16(13):1929-43. PubMed ID: 26219918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply: To PMID 25825070.
    Gutierrez JA; Carrion A; Bhamidimarri KR; Peyton AL
    Liver Transpl; 2015 Oct; 21(10):1330. PubMed ID: 26271051
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Cure S; Guerra I; Cammà C; Craxì A; Carosi G
    J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
    Ruiz I; Feray C; Pawlotsky JM; Hézode C
    Liver Transpl; 2015 Mar; 21(3):408-9. PubMed ID: 25420476
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemodialysis patients with hepatitis C infection are not receiving the new antiviral medications.
    Goodkin DA; Bieber B
    Am J Nephrol; 2015; 41(4-5):302. PubMed ID: 26044708
    [No Abstract]   [Full Text] [Related]  

  • 26. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Simeprevir (Olysio), oral administration].
    Van Broeck D
    J Pharm Belg; 2015 Mar; (1):57-60. PubMed ID: 26571797
    [No Abstract]   [Full Text] [Related]  

  • 28. Direct acting antiviral therapy after liver transplantation.
    Kwo PY
    Curr Opin Gastroenterol; 2016 May; 32(3):152-8. PubMed ID: 27023161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seizures as a Potential Complication of Treatment With Simeprevir and Sofosbuvir.
    Syal G; Heldenbrand SD; Duarte-Rojo A
    Am J Ther; 2016; 23(2):e570-1. PubMed ID: 25549078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir.
    Bernuth S; Yagmur E; Schuppan D; Sprinzl MF; Zimmermann A; Schad A; Kittner JM; Weyer V; Knapstein J; Schattenberg JM; Wörns MA; Galle PR; Zimmermann T
    Dig Liver Dis; 2016 Mar; 48(3):291-7. PubMed ID: 26514736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sofosbuvir (Sovaldi), oral administration].
    Duh D; Van Genechten D
    J Pharm Belg; 2015 Mar; (1):61-3. PubMed ID: 26571798
    [No Abstract]   [Full Text] [Related]  

  • 32. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.
    Gentile I; Maraolo AE; Buonomo AR; Zappulo E; Borgia G
    Expert Opin Drug Discov; 2015 Dec; 10(12):1363-77. PubMed ID: 26563720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
    Tang L; Ward H; Kattakuzhy S; Wilson E; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):21-36. PubMed ID: 26558305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
    Levitsky J; Verna EC; O'Leary JG; Bzowej NH; Moonka DK; Hyland RH; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault NA
    N Engl J Med; 2016 Nov; 375(21):2106-2108. PubMed ID: 27959735
    [No Abstract]   [Full Text] [Related]  

  • 35. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
    Sundaram V; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):13-20. PubMed ID: 26560449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
    McConachie SM; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy for hepatitis C genotype 3: moving forward.
    Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
    J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.